Abstract
Objective
To investigate longitudinal trends in rheumatoid arthritis (RA) diagnosis and monitoring by physicians and advanced practice providers (APPs) as measured by laboratory testing.
Methods
We conducted a retrospective review of RA‐associated diagnostic and monitoring tests ordered through Labcorp by 7,026 physicians and 2,188 APPs in primary care and rheumatology between 2012 and 2024. Diagnostic tests include conventional markers (rheumatoid factor and anti–cyclic citrullinated peptide) and emerging markers (14.3.3 eta protein, anti–citrullinated α‐enolase peptide 1, anti–carbamylated protein, and anti‐citrullinated vimentin antibodies). Panel tests combine these markers to enhance diagnostic accuracy. Monitoring tests include the Vectra tests.
Results
From 2012 to 2024, rheumatology APPs who consistently ordered RA‐associated tests annually through Labcorp increased by 411.8%, whereas rheumatology physicians who consistently ordered RA‐associated tests through Labcorp grew by 58.5%. Compared with rheumatology physicians, rheumatology APPs ordered 37.9 fewer conventional markers (P = 2.7 × 10−12) and 2.4 more monitoring tests (P = 0.019). Between 2012 and 2024, conventional marker volumes increased by 3.0% among rheumatology physicians, 98.9% among rheumatology APPs, 36.2% among primary care physicians, and 75.6% among primary care APPs. The yearly average volume of RA panel tests ordered by rheumatology APPs increased by 2,948.5% compared with increases of 218.4% by rheumatology physicians, 128.0% by primary care physicians, and 203.7% by primary care APPs. The difference in the proportion of positive diagnostic test results between rheumatology physicians and rheumatology APPs narrowed from 3.0% in 2015 to 0.5% in 2024.
Conclusion
We observed a rise in APP contributions to RA‐diagnostic and RA‐monitoring test ordering, consistent with their growing presence within the rheumatology workforce.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint pain and swelling. 1 , 2 The prevalence of RA in the United States 3 , 4 is estimated to be approximately 0.5% to 1%. Diagnosis typically involves a combination of clinical evaluation and laboratory testing based on criteria established by the American College of Rheumatology (ACR) and EULAR. 5 , 6
Historically, rheumatoid factor (RF) was included in the 1987 ACR or EULAR classification criteria. 5 In 2010, the classification criteria were revised to incorporate anti–cyclic citrullinated peptide (CCP) antibody testing. 6 These are considered conventional markers. More recently, additional RA‐associated biomarkers have been commercialized to aid in earlier detection and improve diagnostic confidence. In cases of “seronegative RA,” in which RF and anti‐CCP are absent, emerging markers such as 14.3.3 eta protein and anti–citrullinated α‐enolase peptide 1 (CEP‐1), anti–carbamylated protein (CarP), and anti‐citrullinated vimentin (Sa) antibodies show promise in research and some clinical settings. These emerging markers have been commercially available 7 , 8 , 9 , 10 , 11 , 12 , 13 since 2017. Additionally, multimarker panel tests that combine conventional markers with these newer markers have emerged to enhance diagnostic yield and efficiency.
Concurrently, concerns about the growing demand for rheumatic care and a limited workforce have prompted structural changes in care delivery. A 2007 workforce study projected that the demand for rheumatologists would exceed supply 14 by 2025. A subsequent assessment in 2015 reaffirmed this trend, predicting a 102% shortage of rheumatologists 15 by 2030. In response, health care systems have increasingly integrated advanced practice providers (APPs), such as nurse practitioners and physician assistants, into rheumatology practices. 14 , 16 , 17 Rheumatology APPs help alleviate the demand by evaluating patients, diagnosing rheumatic diseases, prescribing disease‐modifying drugs, and interpreting and delivering test results. 17 , 18 From 2009 to 2020, the number of rheumatology physicians grew by 23%, whereas the number of rheumatology APPs increased by 141%. 16 This growth reflects the expanding role of APPs in supporting rheumatology practices and helping to meet increasing patient care demands. Given these developments in both diagnostic strategies and workforce composition, this study aimed to examine trends in roles in RA diagnosis and monitoring by physicians and APPs in both rheumatology and primary care settings as measured by RA‐associated diagnostic and monitoring test orders.
MATERIALS AND METHODS
We conducted a retrospective review of 9,214 health care providers who ordered RA‐associated diagnostic and/or monitoring tests through Labcorp from 2012 to 2024. Labcorp is a global laboratory testing company that provides diagnostic services across the United States, including the Midwest, Northeast, South, West, and US territories. Although Labcorp is among the largest commercial laboratories in the United States, its data represent only providers who use its services and therefore may not fully capture all RA‐related test ordering nationwide. As such, the findings should only be interpreted in the context of Labcorp's significant market share and geographic distribution. Institutional Review Board approval was not required because only private, de‐identified patient data were used.
RA‐associated tests included conventional markers (RF and anti‐CCP), emerging markers (14.3.3 eta protein, anti–CEP‐1, anti‐CarP, and anti‐Sa antibodies), and monitoring tests (Vectra® and Vectra® with Cardiovascular Risk; Supplementary Table 1). Panel tests refer to laboratory profiles that include various combinations of conventional and emerging markers. For example, the RheumAssure® test is a diagnostic panel test that includes RF, anti‐CCP, and 14.3.3 eta protein antibodies.
Providers were included in the analysis if they ordered a minimum of 10 RF and 10 anti‐CCP tests annually to assess trends in providers who regularly order RA‐associated diagnostic biomarker tests through Labcorp. This threshold was selected to exclude providers who order these tests only sporadically or for reasons unrelated to RA diagnosis and management, thereby improving the likelihood that included providers were actively engaged in RA‐related care. Only physicians and APPs who self‐reported their specialties as rheumatology and/or primary care were included. Primary care specialties encompassed family practice, general practice, and internal medicine. Providers who reported both rheumatology and primary care specialties were categorized as rheumatology providers. Degree and licensure classifications were obtained from the National Provider Identifier database (https://npiregistry.cms.hhs.gov). Physicians were identified as individuals holding a Doctor of Medicine or Doctor of Osteopathic Medicine degree. APPs included advanced practice registered nurses with a Master of Science in Nursing (MSN) or a Doctor of Nursing Practice (DNP) degree, physician assistants with a master's degree in physician assistant studies, and pharmacists with a Doctor of Pharmacy degree. Among primary care APPs, 55.7% were nurse practitioners with an MSN, 2.1% were nurse practitioners with a DNP, and 32.6% were physician assistants. Among rheumatology APPs, 46.1% were nurse practitioners with an MSN, 2.8% were nurse practitioners with a DNP, and 40.6% were physician assistants. These providers were grouped into four categories based on their credentials and specialty: rheumatology physicians, rheumatology APPs, primary care physicians, and primary care APPs.
Normalized testing volumes per year were calculated by dividing the total number of tests ordered by all providers in each category by the number of providers in that category. To assess testing preferences between conventional markers and panel tests, we computed the ratio of average conventional marker testing volume to average panel testing volume per provider. Because RF and anti‐CCP were ordered together in 75% of all anti‐CCP test orders, calculating test‐to‐panel ratios without adjustment would have outweighed these individual assays relative to other tests. To prevent this inflation, the average conventional marker testing volumes for RF and anti‐CCP were divided by 2 before calculating ratios, approximating their independent contributions when frequently co‐ordered.
Monotonic trends over time were determined using the Mann‐Kendall test. Kendall's T indicates the slope of the trend and ranges from −1 (decreasing trend) to 1 (increasing trend). Comparisons of positivity rates between physicians and APPs each year were conducted using two‐sample, two‐sided proportional Z‐tests. P‐values from proportional Z‐tests were adjusted for multiple comparisons using the Benjamini–Hochberg method.
Four separate multivariable linear regression models were used to examine associations between provider categories with average testing volumes of different test categories (conventional markers, emerging markers, panel tests, and monitoring tests). The multivariable linear regression models were adjusted for region and yearly volumes of the other test types. β‐coefficients of categorical variables (provider specialty and type and provider region) from the linear regression models indicate the difference in average ordered tests in comparison to the reference group of each of the variables included in the model. The rheumatology physician category was the reference group for provider categories. β‐coefficients of continuous variables (average conventional markers, average emerging markers, average panel tests, and average monitoring tests) from the linear regression models indicate change in average ordered tests with one unit increase in each of the continuous variables. Statistical significance thresholds were set to P < 0.05.
Data disclosures
The datasets generated and/or analyzed in this study are not publicly available due to proprietary restrictions from Labcorp.
RESULTS
A total of 4,541 primary care physicians, 1,722 primary care APPs, 2,485 rheumatology physicians, and 466 rheumatology APPs who ordered a minimum of 10 RF and 10 anti‐CCP tests per year through Labcorp from 2012 to 2024 were included in the analysis (Table 1). A large proportion of providers across all groups were based in the South, where Labcorp has a strong presence, whereas rheumatology providers had relatively greater representation in the Northeast compared with primary care providers. From 2012 to 2024, the number of APPs who regularly ordered RA‐associated tests through Labcorp grew at a faster rate than physicians in both primary care and rheumatology (Supplementary Figure 1A). Specifically, the number of rheumatology APPs who regularly ordered through Labcorp increased by 411.8%, whereas the number of rheumatology physicians who regularly ordered RA‐associated tests through Labcorp increased by 58.5%. The number of rheumatology APPs who regularly ordered RA‐associated tests, compared with the number of rheumatology physicians, steadily increased from 2012 (physicians to APP ratio 19.4) to 2024 (physicians to APP ratio 6.0; Supplementary Figure 1B). There were six rheumatology physicians who regularly ordered RA‐associated tests for every one rheumatology APP in 2024. In comparison, there were 2.8 primary care physicians who regularly ordered RA‐associated tests for every 1 primary care APP in 2024.
Table 1.
Provider demographics by provider category*
| Primary care | Rheumatology | |||
|---|---|---|---|---|
| Physician | APP | Physician | APP | |
| N | 4,541 | 1,722 | 2,485 | 466 |
| Region, N (%) | ||||
| Midwest | 403 (8.9) | 166 (9.6) | 231 (9.3) | 50 (10.7) |
| Northeast | 744 (16.4) | 158 (9.2) | 641 (25.8) | 87 (18.7) |
| South | 2,302 (50.7) | 959 (55.7) | 1,114 (44.8) | 211 (45.3) |
| West | 1,089 (24.0) | 439 (25.5) | 496 (20.0) | 118 (25.3) |
| US territories | 3 (0.1) | 0 (0) | 3 (0.1) | 0 (0) |
| Conventional markers ordered per year, median [min, max] | 33.8 [12.0, 3,120] | 31.0 [12.5, 697] | 86.0 [16.0, 3,170] | 63.8 [17.8, 901] |
| Emerging markers ordered per year, median [min, max] | 0 [0, 272] | 0 [0, 86.0] | 0 [0, 1,030] | 0 [0, 424] |
| Panel tests ordered per year, median [min, max] | 0 [0, 231] | 0 [0, 164] | 1.0 [0, 485] | 1.0 [0, 283] |
| Monitoring tests ordered per year, median [min, max] | 0 [0, 223] | 0 [0, 36.3] | 0 [0, 554] | 0 [0, 212] |
APP, advanced practice providers; max, maximum; min, minimum.
Test volume differences by provider type
Multivariable linear regression models were performed to evaluate associations between provider categories and ordering levels of RA‐associated tests.
Conventional markers
Compared with rheumatology physicians, rheumatology APPs ordered 37.9 fewer conventional markers per year (β = −37.9, P = 2.7 × 10–12; Figure 1A). Primary care physicians and APPs ordered 82.4 (β = −82.4, P = 9.1 × 10–184) and 91.4 (β = −91.4, P = 6.7 × 10–147) fewer conventional markers per year, respectively.
Figure 1.

RA‐diagnostic test ordering patterns for provider categories. (A) Distribution of yearly average orders for different categories of rheumatoid arthritis–associated diagnostic tests among rheumatology physicians and APPs and primary care physicians and APPs. β‐coefficients and respective P values from comparisons between provider specialties conducted using multivariable linear regression are indicated above each comparison (Supplementary Table 2). (B) Percent change in yearly testing volumes for provider category for each test category comparing 2012 with 2024. Colored by provider category. APP, advanced practice providers; PC, primary care; PHY, physician; RHU, rheumatology.
Emerging markers
Overall volumes of emerging markers were very low across all provider categories, with most averaging fewer than one order per provider per year (Table 1). There was no significant difference in the average volume of emerging markers between rheumatology physicians and rheumatology APPs (β = 1.9, P = 0.19; Figure 1A). However, primary care physicians and APPs ordered on average 4.3 and 4.1 fewer emerging markers per year than rheumatology physicians (β = −4.3, P = 3.5 × 10‐8 and β = −4.1, P = 2.3 × 10−5, respectively).
Panel tests
Ordering of panel tests was minimal across all provider categories, with average volumes of ≤1.0 per provider per year (Table 1). Rheumatology APPs ordered 4.6 fewer panel tests per year than rheumatology physicians (β = −4.6, P = 5.3 × 10−5; Figure 1A). Compared with rheumatology physicians, primary care physicians and APPs ordered 5.0 (β = −5.0, P = 2.9 × 10−16) and 5.4 (β = −5.4, P = 1.1 × 10−12) fewer panel tests, respectively.
Monitoring tests
Similar to emerging markers and panel tests, use of monitoring tests was sparse across all provider categories, with most providers averaging fewer than one order annually (Table 1). However, rheumatology APPs ordered 2.4 more monitoring tests annually than rheumatology physicians (β = 2.4, P = 0.019; Figure 1A). Compared with rheumatology physicians, both primary care physicians and APPs ordered 6.1 (β = −6.1, P = 1.5 × 10−29) and 6.1 (β = −6.1, P = 8.9 × 10−20) fewer monitoring tests per year, respectively.
Contribution to test volumes by provider group
As expected, rheumatology physicians and APPs accounted for the majority of RA‐associated test orders.
Conventional markers
Rheumatology physicians accounted for 53.7% of conventional markers, whereas rheumatology APPs ordered 21.3% of those tests (Supplementary Figure 2A). Compared with primary care physicians and APPs, rheumatology physicians ordered 86.2% and 115.6% more conventional markers, respectively. Additionally, rheumatology physicians ordered 66.5% more conventional markers than rheumatology APPs.
Emerging markers
Rheumatology physicians and APPs accounted for 53.0% and 32.8%, respectively, of the total volume of emerging markers ordered (Supplementary Figure 2A). Rheumatology physicians ordered 11.5% more emerging markers than primary care physicians, 13.5% more than primary care APPs, and 4.6% more than rheumatology APPs.
Panel tests
Rheumatology physicians and APPs accounted for 57.1% and 23.4% of panel test orders, respectively (Supplementary Figure 2A). Rheumatology physicians ordered 7.9% more panel tests than primary care physicians, 8.0% more than primary care APPs, and 5.2% more than rheumatology APPs.
Monitoring tests
Rheumatology physicians and APPs accounted for 43.8% and 37.5% of monitoring test orders, respectively (Supplementary Figure 2A). Rheumatology physicians ordered 5.7% more monitoring tests than primary care physicians, 8.0% more than primary care APPs, and just 1.0% more than rheumatology APPs.
Among patients with monitoring tests, 75.9% took only one monitoring test (Supplementary Figure 3A), and 15.4% took two monitoring tests. A total of 82.1% of patients’ first monitoring tests were ordered by rheumatology physicians, whereas 14.0% were ordered by rheumatology APPs (Supplementary Figure 3B). The proportions of monitoring tests ordered by rheumatology APPs increased with each additional monitoring test up to the fourth test. A total of 17.2% of the fourth monitoring tests were ordered from rheumatology APPs. Among patients with multiple monitoring tests, the second monitoring test was taken a median of 272 days after the first (Supplementary Figure 3C). Although the median interval between monitoring tests decreased with each subsequent test, the median time from the fourth to the fifth monitoring test remained 182 days, which falls within the recommended retest time frame.
Longitudinal trends in test volumes
Conventional markers
Volumes ordered by rheumatology physicians remained stable over time (T = −0.05, P = 0.855; Figure 1B, Supplementary Figure 2B, Supplementary Table 3). In contrast, compared with 2012, test volumes in 2024 increased by 98.9% among rheumatology APPs, 36.2% among primary care physicians, and 75.6% among primary care APPs.
Emerging markers
Orders increased significantly among both rheumatology physicians (T = 0.86, P = 0.004) and rheumatology APPs (T = 0.92, P = 0.002) but remained stable among primary care physicians (T = −0.29, P = 0.386, Figure 1B, Supplementary Figure 2B, Supplementary Table 3). Primary care APPs showed a dramatic spike in test volume in 2018 (781.5%) and 2019 (670.4%), followed by normalization after 2020.
Panel tests
Marked increases were observed from 2021 to 2023 across all groups, particularly among rheumatology APPs (Figure 1B, Supplementary Figure 2B). By 2024, compared with 2012, the average annual volume increased by 2,948.5% for rheumatology APPs, 218.4% for rheumatology physicians, 128.0% for primary care physicians, and 203.7% for primary care APPs.
Monitoring tests
Test volumes rose from 2021 to 2022 among rheumatology physicians and APPs but declined in 2023 and 2024 (Figure 1B, Supplementary Figure 2B).
Test preferences: conventional marker versus panel
We also examined whether provider categories exhibited a preference for conventional marker tests or panel tests. All provider categories showed a greater preference for conventional marker tests over panel tests. However, this preference was less pronounced in APPs and primary care providers. The conventional marker‐to‐panel test ratio was lower by 8.8 for rheumatology APPs compared with rheumatology physicians (P = 0.007; Figure 2A). The ratio was lower by 19.0 for primary care physicians (P = 9.7 × 10−35) and by 21.6 for primary care APPs (P = 3.9 × 10−24), compared with rheumatology physicians. From 2012 to 2024, all groups exhibited a shift toward greater panel test use, especially between 2021 and 2024, likely due to increased commercial availability (Figure 2B). Despite this trend, rheumatology physicians maintained the strongest relative preference for conventional marker testing.
Figure 2.

Preference for conventional marker‐to‐panel testing. (A) Ratio of conventional markers to panel tests by provider category. β‐coefficients from comparisons between provider specialties conducted using multivariable linear regression are indicated above each comparison (Supplementary Table 2). (B) Conventional marker‐to‐panel tests ratio per year by provider category from 2012 to 2024. Colored by provider category. APP, advanced practice providers; PC, primary care; PHY, physician; RHU, rheumatology.
Positivity rates by provider group
Finally, we examined positivity rates of diagnostic tests ordered by provider category per year. From 2012 to 2024, the average positivity rate for diagnostic tests was 31.3% for rheumatology physicians and 29.8% for rheumatology APPs (Figure 3A). In contrast, primary care physicians and APPs had average positivity rates of 18.7% and 15.3%, respectively.
Figure 3.

Positivity rates in diagnostic tests by provider category. (A) Yearly positivity rates and 95% confidence intervals among all diagnostic testing by provider category. Comparisons between physicians and APPs for each specialty were performed with two‐sample, two‐sided proportional Z‐tests. Adjusted P values for each year are indicated in red for comparisons in rheumatology and in blue for primary care. (B) Differences in positivity rates per year between physicians and APPs for each specialty. APP, advanced practice providers; PC, primary care; PHY, physician; RHU, rheumatology.
Between 2015 and 2023, positivity rates for tests ordered by rheumatology physicians were significantly higher than those ordered by rheumatology APPs (Figure 3A). However, this gap narrowed over time (Figure 3B), and by 2024, the difference was not statistically significant (P = 0.07; Figure 3A). Among primary care providers, physicians consistently had higher positivity rates than APPs throughout the study period, with no significant change in this trend from 2012 to 2024 (Figure 3A and 3B).
DISCUSSION
As testing practices and the composition of the rheumatology workforce have evolved over the past couple of decades, this study quantitatively evaluated trends in the ordering of RA‐associated diagnostic and monitoring tests in the United States from 2012 to 2024. Orders from rheumatology APPs increased substantially across all test categories during this period. Panel tests gained use among all provider categories. Rheumatology physicians consistently ordered more conventional markers, emerging markers, and panel tests than rheumatology APPs, whereas the latter ordered more monitoring tests per provider.
Our findings are consistent with broader workforce trends. The rapid growth in test orders by APPs mirrors their increasing role in rheumatology, in which shortages of physicians have been well documented. Notably, rheumatology APPs ordered slightly more monitoring tests per capita than rheumatology physicians, potentially reflecting their involvement in routine follow‐up visits and longitudinal disease activity management. Furthermore, the narrowing diagnostic test positivity gap between rheumatology physicians and APPs by 2024 suggests increasing alignment in diagnostic approaches between the two provider categories. Our study provides quantitative insight into the increasing involvement of rheumatology APPs in RA care.
Although test volumes grew most substantially among APPs, proportional increases should be interpreted with caution. For instance, primary care APPs exhibited a 781.5% increase in emerging marker volumes in 2018 and a 670.4% increase in 2019 relative to 2017. This sharp rise likely reflects the initially small number of primary care APPs ordering these tests, with a few early adopters contributing to large proportional changes before broader uptake occurred in subsequent years. Similarly, rheumatology APPs showed a 2,948.5% increase in panel test volumes in 2024 compared with 2012. Because testing volumes were normalized per provider, these trends suggest that the rise in testing was driven not only by more APPs entering the field but also by an expansion of their role in RA diagnosis.
Panel tests gained increasing use among rheumatology providers following their commercialization, although absolute volumes remained much lower than conventional markers. Conventional markers remain more frequently used; however, the preference for conventional markers over panel testing has declined across all provider groups. This trend is likely to continue as panel tests become more accessible and as providers seek streamlined diagnostic workflows that incorporate both conventional and emerging markers.
A limitation of our study is the reliance on self‐reported provider specialty data. Some providers may practice in multiple specialties beyond primary care and rheumatology, which could affect specialty‐specific comparisons. However, because our study only included providers who ordered a minimum number of RA‐associated tests, we expect the impact of such inaccuracies to be minimal. Another important limitation is that our analysis relies solely on test orders placed through Labcorp. Although Labcorp is one of the largest commercial laboratories in the United States, its dataset may not fully represent all RA‐related testing practices. Providers who order primarily through other commercial laboratories, most hospital‐based laboratories, or academic centers are not captured in these data. As such, our findings may be more reflective of test ordering patterns among providers who use commercial laboratory services and may not generalize to the entire US rheumatology and primary care workforce. Finally, the dataset did not contain financial information such as the cost of testing or insurance coverage. Further research is needed to investigate the economic impact from the changes in trends of ordering patterns of different provider types.
AUTHOR CONTRIBUTIONS
All authors contributed to at least one of the following manuscript preparation roles: conceptualization AND/OR methodology, software, investigation, formal analysis, data curation, visualization, and validation AND drafting or reviewing/editing the final draft. As corresponding author, Dr Lee confirms that all authors have provided the final approval of the version to be published and takes responsibility for the affirmations regarding article submission (eg, not under consideration by another journal), the integrity of the data presented, and the statements regarding compliance with institutional review board/Declaration of Helsinki requirements.
ROLE OF THE STUDY SPONSOR
Labcorp had no role in the study design or in the collection, analysis, or interpretation of the data, the writing of the manuscript, or the decision to submit the manuscript for publication. Publication of this article was contingent upon approval by Labcorp.
Supporting information
Supplementary Figure 1. A) Percentage change in the number of providers who ordered at least 10 RF and 10 anti‐CCP tests, compared to 2012, by provider specialty and type from 2012 through 2024. B) Ratio of number of physicians to number of APP who have ordered RA‐associated testing through Labcorp from 2012 through 2024 for each specialty.
Supplementary Figure 2. A) Proportions of normalized testing volumes by each provider category for each test category. B) Normalized testing volumes for each test category by provider category from 2012 through 2024.
Supplementary Figure 3. A) Proportions of subjects grouped by number of monitoring tests taken through Labcorp® by providers included in this study. B) Proportions of provider categories that ordered patient's first, second, third, fourth, and fifth tests. Up to only fifth tests were considered for downstream analyses. C) Distributions of when a patient's second, third, fourth, or fifth test was taken relative to the previous test. Lines within the boxplot indicate the median days after the previous monitoring test. Lower ends of the boxplots indicate the 25th percentile of the days after the previous monitoring test. Upper ends of the boxplots indicate the 75th percentile of the days after the previous monitoring test.
Supplementary Table 1. List of Labcorp's RA‐associated diagnostic and monitoring tests included in the study.
Supplementary Table 2. Results of multivariable linear regressions to test for associations between provider category with yearly average testing volumes for each test category.
Supplementary Table 3. Monotonic trend test for each test category for each provider category.
Disclosure Form:
Additional supplementary information cited in this article can be found online in the Supporting Information section (https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr2.70185).
Author disclosures are available at https://onlinelibrary.wiley.com/doi/10.1002/acr2.70185.
References
- 1. Guo Q, Wang Y, Xu D, et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 2018;6(1):15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA 2018;320(13):1360–1372. [DOI] [PubMed] [Google Scholar]
- 3. Myasoedova E, Davis J, Matteson EL, et al. Is the epidemiology of rheumatoid arthritis changing? Results from a population‐based incidence study, 1985–2014. Ann Rheum Dis 2020;79(4):440–444. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Hunter TM, Boytsov NN, Zhang X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatol Int 2017;37(9):1551–1557. [DOI] [PubMed] [Google Scholar]
- 5. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315–324. [DOI] [PubMed] [Google Scholar]
- 6. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;69(9):1580–1588. [DOI] [PubMed] [Google Scholar]
- 7. Maksymowych WP, Boire G, van Schaardenburg D, et al. 14‐3‐3η autoantibodies: diagnostic use in early rheumatoid arthritis. J Rheumatol 2015;42(9):1587–1594. [DOI] [PubMed] [Google Scholar]
- 8. Maksymowych WP, Naides SJ, Bykerk V, et al. Serum 14‐3‐3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol 2014;41(11):2104–2113. [DOI] [PubMed] [Google Scholar]
- 9. Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011;108(42):17372–17377. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Brink M, Hansson M, Mathsson L, et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 2013;65(4):899–910. [DOI] [PubMed] [Google Scholar]
- 11. El‐Gabalawy HS, Wilkins JA. Anti‐Sa antibodies: prognostic and pathogenetic significance to rheumatoid arthritis. Arthritis Res Ther 2004;6(2):86–89. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Šenolt L, Grassi W, Szodoray P. Laboratory biomarkers or imaging in the diagnostics of rheumatoid arthritis? BMC Med 2014;12(1):49. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Trouw LA, Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev 2012;12(2):318–322. [DOI] [PubMed] [Google Scholar]
- 14. Deal CL, Hooker R, Harrington T, et al. The United States rheumatology workforce: supply and demand, 2005‐2025. Arthritis Rheum 2007;56(3):722–729. [DOI] [PubMed] [Google Scholar]
- 15. Battafarano DF, Ditmyer M, Bolster MB, et al. 2015 American College of Rheumatology workforce study: supply and demand projections of adult rheumatology workforce, 2015–2030. Arthritis Care Res (Hoboken) 2018;70(4):617–626. [DOI] [PubMed] [Google Scholar]
- 16. Mannion ML, Xie F, FitzGerald JD, et al. Changes in the workforce characteristics of providers who care for adult patients with rheumatologic and musculoskeletal disease in the United States. Arthritis Rheumatol 2024;76(7):1153–1161. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Solomon DH, Bitton A, Fraenkel L, et al. The roles of nurse practitioners and physician assistants in rheumatology practices in the US. Arthritis Care Res (Hoboken) 2014;66(7):1108–1113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Hooker RS, Rangan BV. Role delineation of rheumatology physician assistants. J Clin Rheumatol 2008;14(4):202–205. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplementary Figure 1. A) Percentage change in the number of providers who ordered at least 10 RF and 10 anti‐CCP tests, compared to 2012, by provider specialty and type from 2012 through 2024. B) Ratio of number of physicians to number of APP who have ordered RA‐associated testing through Labcorp from 2012 through 2024 for each specialty.
Supplementary Figure 2. A) Proportions of normalized testing volumes by each provider category for each test category. B) Normalized testing volumes for each test category by provider category from 2012 through 2024.
Supplementary Figure 3. A) Proportions of subjects grouped by number of monitoring tests taken through Labcorp® by providers included in this study. B) Proportions of provider categories that ordered patient's first, second, third, fourth, and fifth tests. Up to only fifth tests were considered for downstream analyses. C) Distributions of when a patient's second, third, fourth, or fifth test was taken relative to the previous test. Lines within the boxplot indicate the median days after the previous monitoring test. Lower ends of the boxplots indicate the 25th percentile of the days after the previous monitoring test. Upper ends of the boxplots indicate the 75th percentile of the days after the previous monitoring test.
Supplementary Table 1. List of Labcorp's RA‐associated diagnostic and monitoring tests included in the study.
Supplementary Table 2. Results of multivariable linear regressions to test for associations between provider category with yearly average testing volumes for each test category.
Supplementary Table 3. Monotonic trend test for each test category for each provider category.
Disclosure Form:
